ArticleMolecular biology reports2026
Ameliorative effects of Chlorophytum borivilianum on atopic dermatitis via modulation of inflammatory biomarkers and GC-MS-based metabolite profiling.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by pruritus, xerosis, and immune dysregulation. Current therapies are often associated with adverse effects and limited long-term compliance. Chlorophytum borivilianum possesses documented anti-inflammatory, antioxidant, and immunomodulatory properties [1]. This study aims to investigate the therapeutic effects of C. borivilianum root extract (CPEx) and dichloromethane fraction (DCMF) in a 2,4-dinitrochlorobenzene (DNCB)-induced Swiss albino mouse model GC-MS analysis identified critical bioactive metabolites, including (6)-shogaol, piperine, and polyunsaturated fatty acids. Topical administration of 4% CPEx and 4% DCMF significantly improved clinical dermatitis scores and reduced epidermal hyperplasia. These improvements were accompanied by significant downregulation of pro-inflammatory cytokine gene expressions (IL-4, IL-6, IL-13, TNF-α). Furthermore, treatment significantly reduced serum IgE levels and restored redox balance by increasing superoxide dismutase (SOD) and catalase (CAT) activities while decreasing malondialdehyde (MDA) and nitric oxide (NO) levels.Histopathological evaluation confirmed the restoration of skin barrier integrity and the reduction of inflammatory cell infiltration. Our results suggest that C. borivilianum exerts potent anti-inflammatory and antioxidant effects through the modulation of the Th2 axis and Nrf2-mediated pathways, establishing its potential as a safe and effective natural candidate for the management of atopic dermatitis.
Indexed as
Identifiers
42126771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.